Hepatitis C News and Research

Latest Hepatitis C News and Research

Dutch researcher sheds new light on coronaviruses

Using novel techniques, Dutch researcher Matthijs Raaben has cast new light on the replication of coronaviruses, a family of viruses including the cause of SARS. He has shown, using luminescent viruses, how coronaviruses use host cells and how we can use the intracellular processes to attack the virus.

21 Oct 2009

Also in Global Health News: Cholera in Zimbabwe; personal computers; medical 'outliers'; rain in Kenya; generic drugs

A cholera outbreak in Zimbabwe has infected more than 100, resulting in five deaths, state media said Tuesday, Reuters reports, "raising fears of a repeat of last year's epidemic that claimed more than 4,000 lives.

21 Oct 2009

Patients with chronic hepatitis C can benefit by drinking coffee

Patients with chronic hepatitis C and advanced liver disease who drink three or more cups of coffee per day have a 53% lower risk of liver disease progression than non-coffee drinkers according to a new study led by Neal Freedman, Ph.D., MPH, from the National Cancer Institute (NCI).

20 Oct 2009

Sudbury and District Public Health Unit nurses to negotiate with their employer for a new contract

Public health nurses with the Sudbury and District Public Health Unit are going to conciliation in their bid to reach a new contract with their employer. Conciliation dates have been set for November 3 and 4, 2009.

20 Oct 2009

Biomagnetics Diagnostics to raise $1 million

Biomagnetics Diagnostics Corp. (Pink Sheets:BMGP), a producer of revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV and hepatitis testing today announced the completion of its equity financing designed to fund entry into the Integrated Optical Biosensor Systems (IOBS) market.

20 Oct 2009

Potential hazards of H1N1 vaccine and seasonal flu shot not disclosed, say protesters

As millions of Americans remain concerned about government-recommended flu shots, dozens of citizens dressed in full haz-mat suits will gather Wednesday, October 21, at the entrance to the Centers For Disease Control (CDC) to greet arriving members of the Advisory Committee on Immunization Practices.

20 Oct 2009

Cangene to acquire U.S. commercialization rights for HepaGam B

Cangene Corporation today announces that it has signed an agreement with its majority shareholder, the Apotex Group, under which Cangene acquires all U.S. commercialization rights for HepaGam B(R) (Hepatitis B Immune Globulin Intravenous (Human)). HepaGam B(R) is Cangene's hepatitis B immune globulin, which is approved for treating two hepatitis-B-related indications in the U.S.

20 Oct 2009

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-52, the first of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus (SLE).

20 Oct 2009

FDA approves GlaxoSmithKline Biologicals' Cervarix for prevention of cervical cancer

The FDA today approved Cervarix, a new vaccine to prevent cervical cancer and precancerous lesions caused by human papillomavirus (HPV) types 16 and 18. The vaccine is approved for use in girls and women ages 10 years through 25 years.

19 Oct 2009

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.

19 Oct 2009

Human Genome Sciences completes Phase 3 development program, earns $75 million from Novartis

Human Genome Sciences, Inc. today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.

19 Oct 2009

Chembio Diagnostics to supply over 2000 PrimaTB STAT-PAK tuberculosis testing kits

Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has agreed to provide over 2,000 PrimaTB STAT-PAK tuberculosis (TB) testing kits which are approved for use in Macaques to the Orangutan Conservancy (OC) to support the organization's continued drive to raise the level of veterinary care at orangutan rehabilitation centers.

19 Oct 2009

Aethlon Medical to present data on HVC patients treated with its Hemopurifier at the 42nd ASN meeting

Aethlon Medical, Inc. disclosed today that clinical data resulting from the treatment of Hepatitis-C (HCV) infected patients with the Aethlon Hemopurifier® will be presented at the 42nd Annual Meeting & Scientific Exposition of the American Society of Nephrology (ASN).

15 Oct 2009

FDA approves Ortho Clinical Diagnostics' anti-HIV 1+2 test for use on VITROS 5600 & 3600 systems

Ortho Clinical Diagnostics today announced U.S. Food and Drug Administration (FDA) approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROS® 5600 Integrated and VITROS® 3600 Immunodiagnostic Systems.

From Ortho-Clinical Diagnostics, Inc. 15 Oct 2009

BioMedReports.Com releases an exclusive interview with spokesman for Biomagnetics Diagnostics

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has released an exclusive interview with a spokesman for Biomagnetics Diagnostics Corp., the company behind a revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV and hepatitis field testing.

15 Oct 2009

UT Southwestern Medical Center awarded $15.7M NIH contract to develop a new virus database

The National Institutes of Health has awarded a $15.7 million contract to UT Southwestern Medical Center and Northrop Grumman Corp. to develop an open-access national online database and analysis resource center that will help scientists study and combat viruses such as those that cause hepatitis, encephalitis, smallpox, acute respiratory distress and dengue fever, as well as newly emerging pathogenic viruses.

15 Oct 2009

Also in Global Health News: 'Delivering as one'; syringe vending machine; hospital preparedness

Rwanda will host a three-day U.N. meeting next week to discuss ways to improve the U.N.'s ability to "provide development assistance in a more coordinated way," the New Times/allAfrica.com reports. "Rwanda is one of the 8 pilot countries implementing the U.N. 'Delivering as One' initiative, as part of the body's reform process," the publication writes. Participants in the meeting will share their experiences and lessons learned from the program since its implementation in 2007 (Gathoni, 10/14).

15 Oct 2009

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009.

14 Oct 2009

Progenics Pharmaceuticals and Wyeth Pharmaceuticals sign license agreement

Progenics Pharmaceuticals, Inc. today announced that it has entered into an agreement with Wyeth Pharmaceuticals, a division of Wyeth under which Progenics is regaining all worldwide rights to the RELISTOR® franchise from Wyeth Pharmaceuticals, which Progenics had previously licensed to Wyeth Pharmaceuticals.

14 Oct 2009

BioMedReports electronic newsletter releases an article about Biomagnetics Diagnostics

Biomagnetics Diagnostics Corp., a producer of revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV, and hepatitis testing, today announced the Company is the subject of a cover page story in the prestigious BioMedReports electronic newsletter and portal.

14 Oct 2009

Hepatitis C News and Research

Latest Hepatitis C News and Research

Dutch researcher sheds new light on coronaviruses

Also in Global Health News: Cholera in Zimbabwe; personal computers; medical 'outliers'; rain in Kenya; generic drugs

Patients with chronic hepatitis C can benefit by drinking coffee

Sudbury and District Public Health Unit nurses to negotiate with their employer for a new contract

Biomagnetics Diagnostics to raise $1 million

Potential hazards of H1N1 vaccine and seasonal flu shot not disclosed, say protesters

Cangene to acquire U.S. commercialization rights for HepaGam B

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

FDA approves GlaxoSmithKline Biologicals' Cervarix for prevention of cervical cancer

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Human Genome Sciences completes Phase 3 development program, earns $75 million from Novartis

Chembio Diagnostics to supply over 2000 PrimaTB STAT-PAK tuberculosis testing kits

Aethlon Medical to present data on HVC patients treated with its Hemopurifier at the 42nd ASN meeting

FDA approves Ortho Clinical Diagnostics' anti-HIV 1+2 test for use on VITROS 5600 & 3600 systems

BioMedReports.Com releases an exclusive interview with spokesman for Biomagnetics Diagnostics

UT Southwestern Medical Center awarded $15.7M NIH contract to develop a new virus database

Also in Global Health News: 'Delivering as one'; syringe vending machine; hospital preparedness

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Progenics Pharmaceuticals and Wyeth Pharmaceuticals sign license agreement

BioMedReports electronic newsletter releases an article about Biomagnetics Diagnostics

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in